Continuous Glucose Monitor (CGM) Interpretation by Decade of Life

What CGM Actually Measures and Why Age Changes the Interpretation

CGM devices measure interstitial glucose every 1-5 minutes, producing an Ambulatory Glucose Profile (AGP) that captures postprandial spikes, nocturnal nadirs, and day-to-day variability that a single fasting draw misses entirely. Age reshapes insulin sensitivity, counter-regulatory hormone responses, and gastric emptying speed, so reference norms must shift with the decade.

The AGP Report: Key Metrics Defined

The international consensus on CGM metrics, published in Diabetes Care and endorsed by the American Diabetes Association, standardizes four core domains [1]:

• Time in Range (TIR): percentage of readings 70-180 mg/dL (clinical diabetes) or 70-140 mg/dL (non-diabetic optimization).
• Time Below Range (TBR): split into Level 1 (54-69 mg/dL) and Level 2 (<54 mg/dL).
• Time Above Range (TAR): split into Level 1 (181-250 mg/dL) and Level 2 (>250 mg/dL).
• Glucose Management Indicator (GMI): sensor-derived HbA1c estimate, calculated as 3.31 + 0.02392 x mean glucose (mg/dL) [2].

Why a Single "Normal Range" Is Insufficient

A landmark CGM study of 57 non-diabetic healthy adults (Freckmann et al., Journal of Diabetes Science and Technology 2007) found mean glucose of 100 ± 8 mg/dL with 97% of readings falling between 71 and 140 mg/dL [3]. That cohort was predominantly middle-aged. Subsequent work showed that adults over 60 spend measurably more time above 140 mg/dL even without a diabetes diagnosis, a pattern tied to reduced first-phase insulin secretion and rising visceral adiposity [4].

The 2019 international consensus statement by Battelino et al., published in Diabetes Care, provides the most-cited reference framework and explicitly notes that "targets should be individualized" based on age, hypoglycemia risk, and comorbidities [1].

CGM Targets in Your 20s: Establishing a Baseline

Adults in their 20s with no metabolic disease tend to show the tightest glucose profiles of any decade. Mean 24-hour glucose typically sits at 89-99 mg/dL, and postprandial excursions above 140 mg/dL are brief.

What "Optimal" Looks Like at This Age

A CGM observational study of 153 non-diabetic adults aged 18-39 by Hall et al. (PLOS Biology 2018) found that participants spent 96% of time below 140 mg/dL during free-living conditions and that the 75th-percentile peak postprandial glucose was 132 mg/dL [5]. Excursions above 160 mg/dL lasting more than 30 minutes were rare and almost always tied to high-glycemic-index meals consumed without accompanying fat or fiber.

Red Flags in the 20s

Persistent mean glucose above 105 mg/dL, CGM-estimated HbA1c (GMI) at or above 5.7%, or postprandial spikes routinely exceeding 160 mg/dL warrant a follow-up fasting insulin and HOMA-IR calculation. These findings in a 20-something may indicate early insulin resistance, polycystic ovary syndrome (PCOS), or the beginning of impaired first-phase secretion [6].

A coefficient of variation (CV) above 36% in a 20-year-old with no diabetes diagnosis is unusual and may suggest reactive hypoglycemia or an eating pattern that alternates between prolonged fasting and large carbohydrate boluses.

CGM Targets in Your 30s: Metabolic Crossroads

The 30s are often the decade when lifestyle-driven metabolic shifts first become visible on CGM. Stress hormones, sleep debt, and reduced spontaneous physical activity start to widen postprandial excursions.

Insulin Resistance Begins Quietly

The Maastricht Study (N=866 participants without known diabetes, age range 40-75 but with substantial 35-39 sub-cohort data) showed that impaired glucose metabolism detected by CGM preceded HbA1c elevation by several years [4]. The ADA classifies prediabetes as fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%; CGM may detect the functional antecedent of that shift earlier [6].

Practical Targets for the 30s

• Mean glucose: 89-104 mg/dL
• TIR (70-140 mg/dL): above 95%
• TAR (>140 mg/dL): below 5%
• TBR (<70 mg/dL): below 1%
• CV: below 36%

These are optimization targets, not diagnostic thresholds. Clinicians at HealthRX typically flag mean glucose above 108 mg/dL combined with TAR above 10% as the prompt for a metabolic work-up.

CGM Targets in Your 40s: Perimenopause, Andropause, and Rising Variability

The 40s introduce hormonal flux that directly affects glucose regulation. Estrogen supports insulin sensitivity through multiple receptor-mediated pathways; declining estrogen in perimenopausal women measurably increases fasting glucose and postprandial excursion amplitude [7].

Hormonal Effects on CGM Patterns

Estrogen loss is associated with a shift toward central adiposity, reduced GLUT-4 translocation efficiency, and higher hepatic glucose output during fasting. A 2021 study in Menopause (N=149 women, ages 42-55) found that perimenopausal women spent on average 8.3 percentage points less time in the 70-140 mg/dL range compared with age-matched pre-menopausal controls, independent of BMI [7].

In men, free testosterone below 300 ng/dL correlates with elevated HOMA-IR and wider CGM glucose swings. Testosterone replacement in hypogonadal men reduced mean CGM glucose by 6.2 mg/dL in a 6-month open-label trial published in Diabetes Care [8].

Targets for the 40s

The same numeric targets as the 30s apply, but TAR should be reviewed in the context of menstrual cycle phase for perimenopausal women. Glucose tends to rise in the luteal phase and fall sharply at menstruation; 14-day CGM wear that captures only one cycle phase will underestimate or overestimate average variability.

CGM Targets in Your 50s: Prediabetes Surveillance

By the mid-50s, the CDC estimates that approximately 38% of U.S. Adults have prediabetes, and a majority are undiagnosed [9]. CGM is increasingly used as a screening and surveillance tool in this decade because it captures the postprandial dysregulation that fasting glucose alone misses.

ADA Screening Context

The ADA 2024 Standards of Care recommend screening for prediabetes and type 2 diabetes in all adults age 35 and older with a BMI <25 if they have one risk factor, and in all adults age 35 and older regardless of weight [6]. CGM is not currently listed as a primary diagnostic tool by the ADA, but its use for monitoring known prediabetes is supported by expert consensus [1].

The PREVIEW trial (N=2,326, multi-site, ages 25-70) demonstrated that lifestyle intervention in prediabetes reduced progression to type 2 diabetes by 56% over 3 years, and CGM-measured glucose variability was a stronger predictor of progression than HbA1c alone in a secondary analysis [10].

What to Watch in the 50s

| Metric | Optimal (50s, non-diabetic) | Prediabetes Alert | |---|---|---| | Mean glucose | 90-108 mg/dL | >108 mg/dL | | GMI | <5.7% | 5.7-6.4% | | TIR (70-140) | >93% | <85% | | TAR (>140) | <7% | >15% | | CV | <36% | >36% |

CGM Targets in Your 60s: Balancing Efficacy and Hypoglycemia Safety

The 60s require a recalibration of targets. Tighter glucose control remains desirable for reducing cardiovascular and microvascular risk, but hypoglycemia becomes progressively more dangerous due to reduced counter-regulatory hormone responses and higher prevalence of cardiac conduction abnormalities.

The ACCORD Lesson

The ACCORD trial (N=10,251, mean age 62.2 years) found that intensive glycemic control targeting HbA1c below 6.0% increased all-cause mortality compared with standard therapy in adults with established type 2 diabetes and high cardiovascular risk [11]. While ACCORD used HbA1c rather than CGM-derived TIR, the mechanistic basis, which includes nocturnal hypoglycemia and arrhythmia risk, maps directly onto CGM's TBR metric.

The ADA 2024 Standards translate this into a specific CGM guideline: for older adults with multiple comorbidities or high hypoglycemia risk, TIR >50% (70-180 mg/dL) with TBR <1% below 70 mg/dL is acceptable, rather than the stricter >70% TIR target applied to healthier patients [6].

Practical CGM Use at 60

• TBR (<70 mg/dL) should stay below 4% in this decade.
• Level 2 hypoglycemia (<54 mg/dL) above 1% is a medication safety red flag requiring immediate prescription review.
• Mean glucose of 110-125 mg/dL may be acceptable if TAR above 180 mg/dL stays below 10% and TBR is controlled.

Continuous glucose monitoring also offers practical fall-prevention value: a sensor alarm set at 80 mg/dL gives a 15-20 minute warning before symptomatic hypoglycemia for most patients on sulfonylureas or insulin [12].

CGM Targets in Your 70s and Beyond: Frailty-Adjusted Goals

Adults 70 and older face the widest spread of metabolic heterogeneity of any age group. A 74-year-old competitive cyclist has fundamentally different glucose physiology than a 74-year-old with moderate frailty, polypharmacy, and early cognitive decline.

ADA and ISPAD Frailty Stratification

The ADA 2024 Standards of Care divide older adults into three functional categories [6]:

1. Healthy older adults with few comorbidities: HbA1c target 7.0-7.5%, CGM TIR >70% in 70-180 mg/dL.
2. Complex/intermediate with multiple chronic conditions or early cognitive impairment: HbA1c 7.5-8.0%, CGM TIR >50%.
3. Very complex/high frailty: HbA1c below 8.5% as the floor, CGM used primarily to detect and prevent hypoglycemia rather than to optimize upper range.

The Endocrine Society's 2019 clinical practice guideline on diabetes in older adults echoes this frailty-stratified approach, stating: "Glycemic targets should be based on health status and individual patient preference rather than age alone" [13].

Hypoglycemia Risk Is the Dominant Concern

A systematic review in Diabetes Care (N=17 studies, Lipska et al. 2017) found that adults over 75 taking sulfonylureas had a 2.3-fold higher rate of severe hypoglycemia requiring emergency care compared with those aged 45-64 [14]. CGM changes this risk profile materially: a retrospective analysis of Medicare beneficiaries (N=15,559) showed that CGM use in insulin-treated older adults reduced emergency department visits for hypoglycemia by 18.6% within 6 months of initiation (P<0.001) [12].

Targets for the 70s (Healthy, Low Frailty)

• Mean glucose: 100-120 mg/dL
• TIR (70-180 mg/dL): above 70%
• TBR (<70 mg/dL): below 4%
• TBR (<54 mg/dL): below 1%
• TAR (>250 mg/dL): below 5%
• CV: below 36%

Glucose Variability: The Metric That Cuts Across Every Decade

Glucose variability, most commonly expressed as CV (standard deviation divided by mean glucose, multiplied by 100), predicts adverse outcomes independent of mean glucose level. A high CV signals that the metabolic control system is struggling to buffer glucose flux, whether from irregular eating, hormonal disruption, overtraining, or impaired insulin secretion.

CV and Cardiovascular Risk

The DEVOTE trial (N=7,637, semaglutide-treated and insulin degludec-treated patients with type 2 diabetes and high CV risk) included glucose variability analysis showing that visit-to-visit HbA1c variability, a proxy for long-run CGM variability, was independently associated with severe hypoglycemia and all-cause mortality, even after adjusting for mean HbA1c [15].

What Drives High CV at Each Decade

• 20s-30s: Irregular meal timing, alcohol, high-intensity intermittent fasting, PCOS.
• 40s-50s: Perimenopausal estrogen flux, shift work, increasing carbohydrate sensitivity.
• 60s-70s: Sulfonylurea or insulin use, gastroparesis, erratic meal patterns due to social isolation.

A CV consistently above 36% should prompt a detailed dietary review and medication reconciliation at any age [1].

How Long Should You Wear a CGM?

The minimum valid wear period for an AGP report is 14 days with at least 70% data capture, per the 2017 international consensus (Danne et al., Diabetes Care) [16]. Shorter wear periods underrepresent nocturnal patterns and weekend behavioral shifts.

For non-diabetic optimization monitoring, 90-day repeat cycles are a common clinical protocol. For patients on insulin, continuous wear or monthly 14-day cycles are standard.

Sensor Selection by Decade

• 20s-50s optimization users: Dexcom G7 or Abbott FreeStyle Libre 3 provide 10-14 day wear with real-time app connectivity.
• 60s-70s with diabetes: Dexcom G7 is FDA-cleared for insulin dosing decisions; the FreeStyle Libre 3 carries the same indication as of its 2023 FDA clearance [17].
• Older adults with dexterity or vision limitations: The Libre 3's larger reader display and optional wearable reader are practical advantages.

Accuracy differences between current-generation sensors are small (MARD 8-9% for both leading devices), but accuracy degrades during rapid glucose change, specifically during postprandial ascent and post-exercise descent. These are the exact moments when older adults face the highest hypoglycemia risk from dosing off a rapidly changing reading [17].

The Longevity-Medicine Perspective on Non-Diabetic CGM Use

An expanding body of physicians working in longevity and metabolic health apply a tighter CGM target range, 70-140 mg/dL rather than 70-180 mg/dL, even for non-diabetic adults. The reasoning: epidemiological data from the ARIC study (N=15,792, 25-year follow-up) showed that adults with fasting glucose 100-109 mg/dL had a 49% higher risk of cardiovascular disease compared with those below 90 mg/dL, even after excluding anyone who progressed to diabetes during follow-up [18].

This does not mean that brief postprandial excursions to 155 mg/dL after a mixed meal carry the same risk. Duration of elevation matters. An excursion to 155 mg/dL that returns to baseline within 60 minutes is physiologically different from sustained glucose at 145 mg/dL throughout most of the waking day.

The practical implication: for health-optimization users in their 30s-50s, TAR above 140 mg/dL exceeding 5% of total time is the threshold that most longevity-medicine clinicians use to prompt dietary or lifestyle intervention, even before any conventional prediabetes diagnosis applies [5].

Putting the Numbers Together: A Decade-by-Decade Reference

| Decade | Mean Glucose Target | TIR Range | TBR Max | CV Max | |---|---|---|---|---| | 20s | 89-99 mg/dL | >96% (70-140) | <1% below 70 | <36% | | 30s | 89-104 mg/dL | >95% (70-140) | <1% below 70 | <36% | | 40s | 90-108 mg/dL | >93% (70-140) | <1% below 70 | <36% | | 50s | 90-108 mg/dL | >93% (70-140) | <1% below 70 | <36% | | 60s | 95-115 mg/dL | >70% (70-180) | <4% below 70 | <36% | | 70s+ healthy | 100-120 mg/dL | >70% (70-180) | <4% below 70 | <36% | | 70s+ frail | Individualized | >50% (70-180) | <4% below 70 | Monitor only |

If your CGM mean glucose exceeds the upper bound for your decade for two or more consecutive weeks, schedule a fasting insulin, fasting glucose, and 2-hour post-load glucose test before assuming the sensor is inaccurate.